NIH-BARDA funding opportunity for rapid diagnostics

4 May 2018
Written by
Staff, Longitude Prize

Can you help create a diagnostic tool for health care providers to better identify resistant bacterial infections? 

Step 2: Up to $100,000 per semi-finalist (maximum of 10 semi-finalists)

Step 2 of the Antimicrobial Resistance (AMR) Diagnostic Challenge is open to all eligible individuals and entities regardless of their participation in Step 1 of this challenge. 

In this Challenge, the NIH and the BARDA are seeking proposals for the development of new, innovative, accurate, and cost-effective in vitro diagnostic tests that would rapidly inform clinical treatment decisions and be of significant clinical and public health utility to combat the development and spread of antibiotic resistant bacteria. Tests of interest will provide novel, innovative solutions for use in inpatient and/or outpatient settings. The goal of the challenge is to identify a diagnostic test that, when utilized, would lead to more rapid clinical decision making such that antibiotic use and/or outcomes of patients infected with resistant pathogens are fundamentally improved compared to current standard of care, and/or reduce transmission of resistant pathogens such that population infection rates significantly decrease.

This may interest Longitude Prize teams who are based in the United States or who have US citizenship. 

Find out more here.

  1. The letter of intent must be submitted by August 3, 2018, at 11:59 p.m. ET, for all “Solvers” planning to submit for the Step 2 (Delivery of Prototype and Analytical Data) stage of the competition.
  2. The prototype in vitro diagnostic device is not to be provided with the submission. 
  3. The Technical Evaluation Panel will use the following 4 criteria for evaluating the Step 2 submissions including: (a) Innovation; (b) clinical significance; (c) diagnostic performance and feasibility; and (d) sample matrix/setting and ease of use/throughput